Editorial label review
Alloy side effects: dry skin
Primary formulary: Estradiol (oral and patch) + oral micronized progesterone; oxybutynin ER for vasomotor symptoms
Quick answer
Dry skin shows up on the FDA labels for the active ingredients Alloy prescribes — Estradiol (oral and patch) + oral micronized progesterone. This page walks through the labelled frequency ranges, what to watch for, and when to call your clinician.
What Alloy prescribes and why it matters for dry skin
Alloy prescribes FDA-approved bioidentical estradiol and oral micronized progesterone, plus oxybutynin ER as a non-hormonal option for vasomotor symptoms. Because Alloy prescribes FDA-approved active ingredients, the labelled adverse-reaction tables from those medications describe the frequencies you should expect. Dry-skin surface applies mainly to transdermal estradiol formulations on the brand formulary.
Common label-level side effects
Sourced from Section 6 (Adverse Reactions) of each FDA-approved PIL.
- Transdermal estradiol PILs (Vivelle-Dot, Estrogel, Divigel) list application-site dermatitis, pruritus, and dry skin at 5–10% in Section 6.1
- Oral estradiol is not associated with systemic dry skin on labelled ADR tables — estrogen typically improves skin hydration
- Prometrium PIL Section 6 lists pruritus at low frequency
Serious label-level warnings
Drawn from Section 5 (Warnings and Precautions) of the FDA-approved PILs — including the estradiol boxed warning where applicable.
- Widespread rash with fever or facial swelling — the estradiol PIL Section 5 flags rare hypersensitivity as urgent
- Jaundice or yellow-tinged skin — hepatic adverse-event signal on both estradiol and Prometrium PILs
When to contact your clinician
Contact your clinician for widespread rash, facial swelling, or yellowing of skin — both estradiol and progesterone labels flag these as urgent.
Call 911 if you develop chest pain, one-sided weakness, sudden severe headache, vision or speech change, or shortness of breath — per the estradiol PIL boxed warning for cardiovascular events.
What to ask your provider
- “Which SKU in the Alloy formulary am I on, and what is its labelled frequency for dry skin?”
- “Is my dry skinlikely a labelled adverse reaction, or something separate that needs its own workup?”
- “Would a different delivery route (patch vs. pill, oral vs. transdermal) change my expected frequency?”
- “What is the plan if dry skindoes not settle within 2–3 cycles?”
Related editorial reading
- Full editorial review of Alloy — formulary, pricing, and clinician model.
- Is dry skin caused by menopause itself? — how the transition presents on its own.
- Estradiol medication page — mechanism, dosing, and full PIL notes.
- Progesterone medication page — secondary ingredient in Alloy's formulary.
- Browse all side-effect matrix pages — 4 brands × 15 symptoms.
Frequently asked questions
- How often does dry skin happen on Alloy?
- Alloy's primary regimen — Estradiol (oral and patch) + oral micronized progesterone; oxybutynin ER for vasomotor symptoms — carries the FDA-labelled adverse-reaction frequencies for dry skin described on this page. Ranges vary from < 1% to 45% depending on the specific active ingredient and delivery route. See the sources block for the exact PIL tables.
- When should I stop Alloy because of dry skin?
- Talk to your clinician immediately if you meet any of the "when to contact" criteria on this page — most estradiol PIL Section 5 warnings require prompt reassessment. Do not stop hormone therapy without medical input; abrupt discontinuation can trigger rebound symptoms.
- Is dry skin on the FDA label for Alloy's medications?
- Dry-skin surface applies mainly to transdermal estradiol formulations on the brand formulary.
- Is dry skin caused by menopause itself?
- Dry skin can appear during the menopause transition for reasons unrelated to hormone therapy. Our /does-menopause-cause/dry-skin explainer covers what the underlying biology is and how clinicians disentangle the transition from the treatment.